Sunshine Guojian Pharmaceutical (Shanghai) Past Earnings Performance
Past criteria checks 4/6
Sunshine Guojian Pharmaceutical (Shanghai) has been growing earnings at an average annual rate of 34.1%, while the Biotechs industry saw earnings growing at 2.5% annually. Revenues have been growing at an average rate of 12.1% per year. Sunshine Guojian Pharmaceutical (Shanghai)'s return on equity is 6.4%, and it has net margins of 29.1%.
Key information
34.1%
Earnings growth rate
30.6%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 12.1% |
| Return on equity | 6.4% |
| Net Margin | 29.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You
Jul 25
Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?
Jun 20If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity
May 24We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings
Mar 31Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04Revenue & Expenses Breakdown
How Sunshine Guojian Pharmaceutical (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,133 | 329 | 321 | 300 |
| 31 Mar 24 | 1,074 | 352 | 309 | 275 |
| 31 Dec 23 | 1,014 | 295 | 308 | 282 |
| 30 Sep 23 | 1,044 | 243 | 321 | 303 |
| 30 Jun 23 | 963 | 151 | 324 | 296 |
| 31 Mar 23 | 872 | 82 | 332 | 309 |
| 31 Dec 22 | 825 | 49 | 339 | 313 |
| 30 Sep 22 | 828 | 14 | 347 | 354 |
| 30 Jun 22 | 791 | -12 | 329 | 388 |
| 31 Mar 22 | 934 | 50 | 344 | 423 |
| 31 Dec 21 | 929 | 18 | 368 | 455 |
| 30 Sep 21 | 697 | -155 | 387 | 420 |
| 30 Jun 21 | 783 | -137 | 452 | 390 |
| 31 Mar 21 | 757 | -148 | 463 | 366 |
| 31 Dec 20 | 655 | -217 | 466 | 340 |
| 30 Sep 20 | 1,009 | 117 | 463 | 322 |
| 30 Jun 20 | 1,011 | 154 | 450 | 313 |
| 31 Mar 20 | 1,155 | 194 | 569 | 296 |
| 31 Dec 19 | 1,177 | 229 | 570 | 279 |
| 31 Dec 18 | 1,142 | 370 | 473 | 199 |
| 31 Dec 17 | 1,103 | 389 | 445 | 122 |
| 31 Dec 15 | 877 | 211 | 456 | 0 |
| 31 Dec 14 | 776 | 212 | 455 | 0 |
| 31 Dec 13 | 728 | 295 | 342 | 0 |
Quality Earnings: 688336 has a large one-off gain of CN¥92.6M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 688336's current net profit margins (29.1%) are higher than last year (15.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688336's earnings have grown significantly by 34.1% per year over the past 5 years.
Accelerating Growth: 688336's earnings growth over the past year (117.8%) exceeds its 5-year average (34.1% per year).
Earnings vs Industry: 688336 earnings growth over the past year (117.8%) exceeded the Biotechs industry 10.1%.
Return on Equity
High ROE: 688336's Return on Equity (6.4%) is considered low.